0
Upcoming Allied Market Research
2023
Pediatric Drugs Market

Pediatric Drugs Market

by Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, Other Drug Types), by Route of Administration (Oral, Topical, Parenteral, Other Routes of Administration) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A50560
Pages: NA
May 2023 | 32 Views
Author(s) : Onkar S
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 
Pediatric drugs are specifically designed and formulated for children, from newborns up to 18 years of age. Children have unique physiological and pharmacological characteristics, which make it essential to develop and test drugs that are safe and effective for them. Development of pediatric drugs has been historically challenging due to ethical and practical considerations. Children are vulnerable and the risks of testing drugs on them need to be balanced against the potential benefits. In addition, children may have different responses to drugs than adults due to differences in their body size, organ function, and metabolic rate.
To encourage development of safe and effective pediatric drugs, regulatory agencies around the world have established guidelines and initiatives that provide incentives and support to pharmaceutical companies to conduct research and development of pediatric drugs. These initiatives include the Pediatric Research Equity Act (PREA) in the U.S., which requires pharmaceutical companies to study the safety and efficacy of their drugs in children when the drug is also being studied in adults. Development of pediatric drugs is crucial for treating childhood illnesses and improving child health outcomes. Many drugs used in children today are off-label or have not been adequately tested in children, which can lead to unexpected side effects or ineffective treatments. Developing pediatric drugs ensures that children receive safe and effective treatments for their specific medical needs.
Common pediatric drugs include antibiotics, asthma medications, and medications for attention deficit hyperactivity disorder (ADHD), among others. These drugs are formulated and dosed to suit the unique needs of children and are often available in liquid or chewable form to make administration easier. 
In recent years, there has been a growing awareness among parents and healthcare professionals about the importance of child healthcare. This has resulted in an increase in number of children being diagnosed and treated for various health conditions, which has driven the growth of the pediatric drugs market.
Parents are becoming more aware of the importance of preventative healthcare and regular check-ups for their children. They are also more likely to seek medical advice and treatment for their children when they notice signs of illness or health issues. This increased awareness has led to earlier detection and diagnosis of health conditions in children, which in turn has increased the demand for pediatric drugs. Healthcare professionals are also contributing to this trend by educating parents and caregivers about the importance of child healthcare. They are providing more resources and information to help parents make informed decisions about their child's health, and are also actively diagnosing and treating more children for various health conditions.
In addition, rise of social media and online health resources has made it easier for parents to access information and connect with other parents and healthcare professionals, which has further increased awareness about child healthcare. Overall, the growing awareness about child healthcare is a positive trend that is driving the growth of the pediatric drugs market. As more children are diagnosed and treated for various health conditions, the demand for effective and safe pediatric drugs is likely to continue to grow. 
Development of innovative pediatric formulations has been a key driver in growth of the pediatric drugs market. Traditionally, administering drugs to children has been a challenge due to difficulties in swallowing pills or tablets, unpleasant taste, and other issues related to the dosing and administration of medicines. However, the development of innovative pediatric formulations such as chewable tablets, oral suspensions, and flavored syrups has made it easier to administer drugs to children, which has increased their acceptance of treatment.
Chewable tablets are easy for children to take and can come in various flavors, making them more palatable. They are also available in a variety of dosages, making it easier for healthcare professionals to tailor the medication to the child's specific needs. Flavored syrups are another form of liquid medication that can be easily administered to children. They are often used for antibiotics, pain relievers, and cough and cold medications, and come in a range of flavors to suit different taste preferences. Overall, the development of innovative pediatric formulations has been a key driver of the growth in the pediatric drugs market, as it has made it easier to administer drugs to children, increased their acceptance of treatment, and improved medication compliance. 
 
New product launches to flourish in the market
In September 2022, Roche announced the launch of its new pediatric cancer drug, Polivy (polatuzumab vedotin-piiq), in the United States. Polivy is a CD79b-directed antibody-drug conjugate, and is indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma in pediatric patients. Moreover, in August 2022, Novartis announced the launch of its new pediatric asthma treatment, Atectura Breezhaler (indacaterol acetate/glycopyrronium bromide), in the European Union. Atectura Breezhaler is a long-acting beta2-agonist/long-acting muscarinic antagonist combination, and is indicated for the maintenance treatment of asthma in children aged 6 to 11 years. Furthermore, in May 2022, Eli Lilly and Company announced the approval of its new pediatric migraine treatment, Emgality (galcanezumab-gnlm), in the United States. Emgality is a calcitonin gene-related peptide (CGRP) antagonist, and is indicated for the preventive treatment of migraine in pediatric patients aged 6 to 17 years.
Segment Overview: 
By Drug Type: The pediatric drugs market is divided into Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs and Other Drug Types. Respiratory Disorder Drugs are drugs used to treat respiratory conditions such as asthma, bronchitis, and other lung diseases. Examples include inhaled corticosteroids, bronchodilators, and leukotriene modifiers. Autoimmune Disorder Drugs are drugs used to treat autoimmune disorders, which occur when the immune system attacks the body's own tissues. Examples include corticosteroids, immunosuppressants, and biologic therapies. Gastrointestinal Drugs are drugs used to treat digestive disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and peptic ulcer disease. Examples include proton pump inhibitors, H2 blockers, and anti-inflammatory drugs. Moreover, cardiovascular Drugs are drugs used to treat heart and blood vessel disorders, such as high blood pressure and congenital heart defects. Examples include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics. Moreover, other drug types includes drugs used to treat a variety of other conditions, such as pain, infections, and neurological disorders. Examples include antibiotics, anticonvulsants, and analgesics.
 
By Route of Administration: The pediatric drugs market is divided into Oral, Topical, Parenteral, and Other Routes of Administration. Oral refers to drugs that are taken by mouth, such as tablets, capsules, syrups, or suspensions. When it comes to topical it refers to drugs that are applied to the skin, such as creams, ointments, or gels. Parenteral refers to drugs that are given by injection or infusion, such as intravenous (IV) or intramuscular (IM) injections. In addition, other routes include other less common routes of administration, such as inhalation or rectal suppositories. 
 
By Region: The Asia Pacific pediatric drugs market is one of the fastest-growing markets in the world, with a significant increase in demand for pediatric medicines over the past few years. Several factors have contributed to the growth of the market in the Asia Pacific region, including increasing healthcare expenditure, rising awareness about child health, and a growing incidence of chronic diseases in children. One of the key drivers of growth in the Asia Pacific pediatric drugs market is the increasing healthcare expenditure in the region. Many countries in the region, including China, India, and Japan, have been increasing their healthcare spending in recent years, which has resulted in a greater demand for healthcare products and services, including pediatric drugs.
 
In addition, there is a growing awareness among parents and healthcare professionals in the Asia Pacific region about the importance of child health. This has resulted in an increase in the number of children being diagnosed and treated for various health conditions, which in turn has driven demand for pediatric drugs. Another factor contributing to the growth of the Asia Pacific pediatric drugs market is the rising incidence of chronic diseases in children. Chronic diseases such as asthma, diabetes, and heart disease are becoming more common among children in the region, which has created a growing demand for drugs to treat these conditions.
 
Competitive analysis and profiles of the major players in the pediatric drugs market, such as BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, PTC Therapeutics Inc., Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., Jazz Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline plc., Johnson & Johnson, and Boehringer Ingelheim International GmbH are included in the report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the pediatric drugs market.  

Pediatric Drugs Market Report Highlights

Aspects Details
By Drug Type
  • Respiratory Disorder Drugs
  • Autoimmune Disorder Drugs
  • Gastrointestinal Drugs
  • Cardiovascular Drugs
  • Other Drug Types
By Route of Administration
  • Oral
  • Topical
  • Parenteral
  • Other Routes of Administration
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, PTC Therapeutics Inc., Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., Jazz Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson, Boehringer Ingelheim International GmbH
Novartis, Sanofi SA
 

Loading Table Of Content...


 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Pediatric Drugs Market

Start reading.
This Report and over 19,981+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers